Bridgebio Pharma Share Price Today (NASDAQ: BBIO)

Name: Bridgebio Pharma Share Price (NASDAQ: BBIO) - Stock Quote, Live Chart
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Bridgebio Pharma share price is $39.77 & ₹3,422.81 as on 14 Jun 2025, 01.29 hrs IST

$39.77

▲

0.12

(0.3%)

Market is closed - opens 7 PM, 16 Jun 2025

View live Bridgebio Pharma share price in Dollar and Rupees. Guide to invest in Bridgebio Pharma stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Bridgebio Pharma, along with analyst recommendations, forecasts, and comprehensive financials.

Bridgebio Pharma share price movements

Today's Low: $38.97
Today's High: $39.81
$39.77
2.01%
Downside
Day's Volatility :2.11%
Upside
0.1%
52 Weeks Low: $21.62
52 Weeks High: $40.40
$39.77
45.64%
Downside
52 Weeks Volatility :46.49%
Upside
1.56%

Bridgebio Pharma (BBIO) Returns

Period	Bridgebio Pharma Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	20.48%	-6.1%	0.0%
6 Months	43.52%	-3.4%	0.0%
1 Year	42.75%	-6.7%	0.0%
3 Years	490.06%	13.0%	3.6%

Bridgebio Pharma (BBIO) Key Statistics

in dollars & INR

Previous Close	$39.65
Open	$39.22
Today's High	$39.81
Today's Low	$38.97
Market Capitalization	$7.4B
Today's Volume	$2.6M
52 Week High	$40.4
52 Week Low	$21.62
Revenue TTM	$127.4M
EBITDA	$-662.6M
Earnings Per Share (EPS)	$-3.47
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-1789.67%

How to invest in Bridgebio Pharma Stock (BBIO) from India?

It is very easy for Indian residents to invest directly in Bridgebio Pharma from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Bridgebio Pharma stock in both Indian Rupees (INR) and US Dollars (USD). Search for Bridgebio Pharma or BBIO on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Bridgebio Pharma or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Bridgebio Pharma shares which would translate to 0.022 fractional shares of Bridgebio Pharma as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India , including recognised companies like Bridgebio Pharma, in just a few clicks!

Returns in Bridgebio Pharma (BBIO) for Indian investors in Rupees

The Bridgebio Pharma stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Bridgebio Pharma investment value today

Current value as on today

₹1,45,788

Returns

₹45,788

(+45.79%)

Returns from Bridgebio Pharma Stock

₹42,749 (+42.75%)

Dollar Returns*

₹3,039 (+3.04%)

Indian investors sentiment towards Bridgebio Pharma (BBIO)

17%

Period: May 14, 2025 to Jun 13, 2025. Change in 30 Days versus previous period

Search interest for Bridgebio Pharma Stock from India on INDmoney has increased by 17% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Bridgebio Pharma

Viking Global Investors LP
11.62%
Kohlberg Kravis Roberts & Co LP
10.14%
Vanguard Group Inc
7.85%
BlackRock Inc
7.03%
HHG PLC
3.78%
Aisling Capital Management LP
3.20%

Analyst Recommendation on Bridgebio Pharma

Rating

Trend

Buy

85%Buy

15%Hold

0%Sell

Based on 20 Wall street analysts offering stock ratings for Bridgebio Pharma(by analysts ranked 0 to 5 stars)

Analyst Forecast on Bridgebio Pharma Stock (BBIO)

What analysts predicted

Upside of 48.91%

Target:

$59.22

Current:

$39.77

Insights on Bridgebio Pharma Stock (Ticker Symbol: BBIO)

Price Movement
In the last 6 months, BBIO stock has moved up by 44.7%
Increasing Revenue
Revenue is up for the last 4 quarters, 2.16M → 116.63M (in $), with an average increase of 56.4% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -265.05M → -167.42M (in $), with an average increase of 58.3% per quarter
BBIO vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 91.7% return, outperforming this stock by 49.0%
Price to Sales
ForBBIO every $1 of sales, investors are willing to pay $59.0, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $16.8 for every $1 of sales.

Bridgebio Pharma Technicals Summary

Sell

Neutral

Buy

Bridgebio Pharma is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Bridgebio Pharma (BBIO) Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Bridgebio Pharma Inc	17.87%	43.52%	42.75%	490.06%	27.84%
Regeneron Pharmaceuticals, Inc.	-9.61%	-27.05%	-48.98%	-5.77%	-10.46%
Beone Medicines Ltd	19.44%	52.93%	65.87%	97.21%	57.25%
Vertex Pharmaceuticals Incorporated	4.88%	-2.68%	-5.24%	79.7%	70.13%
Alnylam Pharmaceuticals, Inc.	8.48%	26.01%	91.68%	126.98%	139.48%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Bridgebio Pharma Inc	NA	NA	NA	-2.34	-17.9	-0.48	NA	-8.68
Regeneron Pharmaceuticals, Inc.	13.31	13.31	1.07	35.45	0.16	0.07	0.01	277.5
Beone Medicines Ltd	NA	NA	NA	1.39	-0.11	-0.03	NA	32.42
Vertex Pharmaceuticals Incorporated	32.84	NA	2.66	18.0	-0.06	0.12	NA	64.2
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	0.93	-15.01	-0.02	NA	0.89

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Bridgebio Pharma Inc	Buy	$7.4B	27.84%	NA	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$56.0B	-10.46%	13.31	31.94%
Beone Medicines Ltd	NA	$32.0B	57.25%	NA	-9.4%
Vertex Pharmaceuticals Incorporated	Buy	$116.2B	70.13%	32.84	-8.91%
Alnylam Pharmaceuticals, Inc.	Buy	$38.9B	139.48%	NA	-11.49%

Bridgebio Pharma Dividend announcements

Bridgebio Pharma Earnings
Bridgebio Pharma’s price-to-earnings ratio stands at None

About Bridgebio Pharma

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; low-dose infigratinib, a treatment option for children living with hypochondroplasia, a skeletal dysplasia closely related to achondroplasia which is in Phase 2/3. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. The company has license and collaboration agreements with the Alexion Pharma International Operations Unlimited Company, Leland Stanford Junior University and Leidos Biomedical Research, Inc., and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.

Organization	Bridgebio Pharma
Employees	725
CEO	Dr. Eric Michael David J.D., M.D., Ph.D.
Industry	Health Technology

Management People of Bridgebio Pharma

Name	Title
Dr. Neil Kumar Ph.D.	Co-Founder, CEO & Director
Dr. Thomas Trimarchi Ph.D.	CFO & President
Dr. Charles J. Homcy M.D.	Co-Founder, Chairman of Pharmaceuticals & Independent Lead Director
Dr. Frank P. McCormick Ph.D.	Co-Founder, Chairman of Oncology & Director
Ms. Maricel M. Apuli	Chief Accounting Officer
Dr. Uma Sinha Ph.D.	Chief Scientific Officer
Dr. Richard H. Scheller Ph.D.	Chairman of Research & Development
Mr. Eli M. Wallace Ph.D.	Chief Scientific Officer of Oncology
Dr. Eric Michael David J.D., M.D., Ph.D.	Chief Executive Officer of Gene Therapy
Mr. Matthew Outten CPC, MBA	Chief Commercial Officer

Important FAQs about investing in BBIO Stock from India :

Can Indians buy Bridgebio Pharma shares?

Yes, Indians can invest in the Bridgebio Pharma (BBIO) from India.

With INDmoney, you can buy Bridgebio Pharma at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Bridgebio Pharma at zero transaction cost.

How can I buy Bridgebio Pharma shares from India?

It is very easy to buy Bridgebio Pharma from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Bridgebio Pharma (BBIO) be purchased?

Yes, you can buy fractional shares of Bridgebio Pharma with INDmoney app.

What are the documents required to start investing in Bridgebio Pharma stocks?

To start investing in Bridgebio Pharma, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What is Bridgebio Pharma share price today?

Bridgebio Pharma share price today stands at $39.77, Open: $39.22 ; Previous Close: $39.65 ; High: $39.81 ; Low: $38.97 ; 52 Week High: $40.40 ; 52 Week Low: $21.62.

The stock opens at $39.22, after a closing price of $39.65. The stock reached a daily high of $39.81 and a low of $38.97, with a 52-week high of $40.40 and a 52-week low of $21.62.